Bushen Culuan Decoction Ameliorates Premature Ovarian Insufficiency by Acting on the Nrf2/ARE Signaling Pathway to Alleviate Oxidative Stress
article
OA: gold
CC0
⤵ 1 in-corpus citation
Abstract
Premature ovarian insufficiency (POI) can result in lower fertility and shorten the female reproductive span. Bushen-Culuan Decoction (BCD) is a traditional Chinese medication utilized for treating POI for many years. We previously observed that BCD protects against further deterioration of the ovarian reserve of POI patients, however, the underlying mechanism has not been well studied. Our investigation seeks to evaluate the effect of BCD on POI induced by Tripterygium wilfordii polyglycosidium (TWP) and the likely mechanistic pathways, which we hypothesize may involve the Nrf2/ARE pathway. The body weights, estrous cycle, serum hormone levels, histological follicular analysis and quantification, levels of oxidative stress biomarkers in the ovarian tissue of POI mice models were evaluated. Western blotting and RT-PCR enabled quantification of the components of the Nrf2/ARE pathway. Our results showed that BCD restored hormonal profiles and estrous cycles of POI mice similar to those observed in healthy controls. BCD reduced the numbers of atretic follicles while increasing the number of primordial follicles. BCD facilitated lower 8-OHdG and MDA levels while increasing levels of key antioxidant enzymes including GSH-Px, CAT, and SOD. Furthermore, TWP increased Bach 1, Nrf2, and Keap 1 expressions at the translational level, while decreased that of HO-1. BCD treatment also promoted nuclear translocation rates of Bach 1 and Nrf2, suppressed Keap 1 protein expression, as well as raised HO-1 protein expression. Taken together, BCD likely augments ovarian reserve by activating the Nrf2/ARE signaling pathway, which stimulated higher levels of antioxidants and suppressed oxidative stress. BCD may be an important therapeutic compound in POI.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (1)
Cited by (1)
References (53)
- Serum biomarker analysis in patients with premature ovarian insufficiency via openalex
- W2028051464 via openalex
- W2038294557 via openalex
- W2072492365 via openalex
- W2073720395 via openalex
- W2096022216 via openalex
- W2135935849 via openalex
- W2148070806 via openalex
- W2295740380 via openalex
- W2345380996 via openalex
- W2504924781 via openalex
- W2605089163 via openalex
- W2605479380 via openalex
- W2609663069 via openalex
- W2734884235 via openalex
- W2754960119 via openalex
- W2758923973 via openalex
- W2761503586 via openalex
- W2793912994 via openalex
- W2810322462 via openalex
- W2885777793 via openalex
- W2888676896 via openalex
- W2889401286 via openalex
- W2894101807 via openalex
- W2912691889 via openalex
- W2920252094 via openalex
- W2924971134 via openalex
- W2934561397 via openalex
- W2938588875 via openalex
- W2940530514 via openalex
- W2945135792 via openalex
- W2945321130 via openalex
- W2965518391 via openalex
- W2974125909 via openalex
- W2978760775 via openalex
- W2984706368 via openalex
- W2990865979 via openalex
- W2995961938 via openalex
- W2998785967 via openalex
- W2999639557 via openalex
- W3001508918 via openalex
- W3001951971 via openalex
- W3003000931 via openalex
- W3004035368 via openalex
- W3004131412 via openalex
- W3009761768 via openalex
- W3024575482 via openalex
- W3025282923 via openalex
- W4211262799 via openalex
- W6697066668 via openalex
- W6704784646 via openalex
- W2000395081 via openalex
- W6759654793 via openalex
Cited by (1)
Source provenance
- europepmc
- last seen: 2026-06-11T06:19:48.454388+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK